For instance, in ovarian cancer, histone acetylation promotes oncogene expression, while dysregulated histone deacetylase (HDAC) activity is implicated in ovarian and endometrial cancers, positioning HDAC inhibitors as promising therapies.30 Here, HDAC9 is linked to ovarian carcinoma.